As an amylin receptor agonist, Cagrilintide acts through a fundamentally different pathway compared to incretin-based peptides like Retatrutide
Medical therapies for IBD include oral or rectal 5-ASA drugs, immunomodulators, biologicals, and other newer agents with different targets and mechanisms of action For patients with mild to moderate UC, 5-ASA drugs are effective for achieving remission and maintenance Rarely, patients have serious adverse events with 5-ASA drugs (eg, interstitial nephritis, pericarditis, pneumonitis, hepatitis, or pancreatitis) Antibiotics Controlled trials of various antibiotics have not demonstrated efficacy in treating UC
Injection-site and general considerations Beyond sterility, subcutaneous injection carries the ordinary risks of any injection: local irritation, bruising, nodules, and the possibility of allergic or hypersensitivity reactions
Recommended Injection Sites: Abdomen (2 inches from navel in any direction) Upper thighs (front or outer aspects) Upper arms (if administered by a partner) Rotate injection sites to prevent tissue irritation and lipohypertrophy Injection Supplies: 29-31 gauge insulin syringes (smaller gauge = less discomfort) 0.5-1ml syringe capacity 12.7mm (1/2 inch) needle length Alcohol swabs for site preparation Sharps container for safe needle disposal Injection Procedure: Wash hands thoroughly and prepare injection site with alcohol swab Allow alcohol to dry completely (prevents stinging) Pinch skin gently to create a fold of subcutaneous tissue Insert needle at 45-90 degree angle (depending on body fat thickness) Inject slowly and steadily over 5-10 seconds Withdraw needle and apply gentle pressure if needed Dispose of needle safely in sharps container Reconstitution Instructions 5-Amino-1MQ typically arrives as lyophilized (freeze-dried) powder requiring reconstitution before use
